These therapies have largely proven most effective in ligand-dependent pre-clinical models but have shown limited efficacy in ligand-independent cancer models, typically due to constitutively active WNT signalling arising from mutations in WNT pathway components that operate downstream of Frizzled receptors, such as in CTNNB1 and APC. This evidence concerns the gene APC and cancer.